Your session is about to expire
← Back to Search
Regorafenib + Nivolumab for Osteosarcoma
Study Summary
This trial is testing a new combination therapy for people with a certain type of bone cancer that has returned or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken a medication that is still being tested in research within the last 28 days before joining this study.I am taking warfarin for blood thinning.My lungs are working well.I haven't had major surgery or serious injuries in the last 28 days.I haven't had chemotherapy that lowers blood cell counts in the last 3 weeks.My heart is functioning well.I had treatment for brain metastases and have shown no signs of worsening for 4 weeks.I have had a serious blood clot that needed blood thinners in the last 6 months.My cancer is a high-grade osteosarcoma not linked to Paget's disease or outside the bones.I can take care of myself and am up and about, even if I use a wheelchair.It has been over a week since my last biologic (cancer) treatment.It has been over 2 months since my last stem cell transplant or cellular therapy.Your hemoglobin level is at least 8 grams per deciliter, and you are allowed to receive blood transfusions if needed.I am 5 years old or older.I have not received a live vaccine in the last 30 days.I am taking or need strong medication that affects liver enzymes.I have had a bowel perforation or developed a fistula in the past.I have a tumor that can be measured on a scan, taken within the last 21 days.I have been treated with drugs targeting the immune system or blood vessel growth.I am at least 5 years old.My cancer is a high-grade osteosarcoma, not linked to Paget's disease or outside the bones.I can swallow pills whole.My heart failure is not severe.You have an autoimmune disease.I haven't had a heart attack, stroke, or serious heart rhythm problems in the last 6 months.I am not pregnant or nursing.It's been enough time since my last radiation therapy as required.I have a severe gut condition causing major diarrhea.I agree to use effective birth control during and after the study as required.I have not had severe bleeding in the last 28 days.My body surface area is less than 0.4 square meters.I have fluid in my chest or abdomen causing significant breathing problems.It's been over a week since I last received treatment to boost my white blood cells or platelets, and over two weeks since my last pegfilgrastim dose.My organs and bone marrow are functioning well.Any side effects from my previous treatments are mild or stable.I have had a stem cell or organ transplant in the past.I am allergic to ingredients in regorafenib, nivolumab, or similar drugs.I can take care of myself and do most of my daily activities.My osteosarcoma has returned or didn't respond after initial treatment.I have a tumor that can be measured on a scan, taken within the last 21 days.I regularly take medication that weakens my immune system.My osteosarcoma has returned or didn't respond after initial treatment.You have enough platelets in your blood (at least 75,000 per cubic millimeter).I have been diagnosed with active HIV.My blood pressure is not controlled by medication.I am over 18 and agree to have tumor biopsies for the study, or I have an exception approved by the study leader.I don't have another cancer that could affect this trial's safety or results.It has been over 3 weeks since I last received treatment with a monoclonal antibody.You have a sufficient amount of a type of white blood cell called neutrophils.I have a wound, ulcer, or fracture that is not healing.I do not have any infections that are not responding to treatment.My liver function tests are within the required range.
- Group 1: Regorafenib and Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What research has been conducted involving Nivolumab besides this current study?
"Presently, 87 Phase 3 trials studying Nivolumab are ongoing with 762 total clinical studies taking place. Basel, BE is home to many of the trialling locations while a total of 41032 sites worldwide have recruited participants for this research."
Is this an innovative clinical trial?
"Nivolumab has been the subject of numerous studies since its initial trial in 2012, sponsored by Ono Pharmaceutical Co. Ltd. The Phase 1 and 2 drug approval was granted following 659 participants being trialled. At present, there are 762 clinical trials for Nivolumab around the globe with locations in 50 countries spread across 2448 cities."
How many participants are being recruited for this research endeavor?
"To complete this trial, 48 participants that satisfy the eligibility requirements must be admitted. Potential enrollees can access these services at UT Southwestern Medical Center in Dallas and Johns Hopkins Hospital in Baltimore."
What is the regular application of Nivolumab in medical practice?
"Nivolumab is often employed to treat malignant neoplasms, and it has also been found useful for managing unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
Is this investigation currently enrolling individuals?
"Affirmative. Clinicaltrials.gov has registered that this trial, originally published on June 4th 2021, is still accepting recruits. 48 individuals are sought out from 9 distinct clinical sites."
To what extent does Nivolumab pose a hazard to individuals?
"With limited clinical data available to prove Nivolumab's efficacy, the safety rating for this drug was assigned a 2."
What is the geographic scope of this experiment?
"Nine medical centres are involved in this clinical trial. Participating locations include UT Southwestern Medical Center (Dallas), Johns Hopkins (Baltimore) and University of Miami (Miami). Additionally, there is a handful of other sites contributing to the study."
Share this study with friends
Copy Link
Messenger